Skip to main content
. Author manuscript; available in PMC: 2021 Aug 20.
Published in final edited form as: Cell. 2020 Jul 24;182(4):992–1008.e21. doi: 10.1016/j.cell.2020.06.037

Figure 5. scCC Uncovers Bromodomain-Dependent Cell-State Dynamics in K562 Cells.

Figure 5.

(A) Gradient of cell states from scRNA-seq analysis of K562 cells.

(B) Differential BRD4 binding analysis of undirected HyPBase peaks in K562 cells.

(C) Representative distributions of CD24high and CD24low cells after either 96 h of DMSO (top) or JQ1 (bottom) treatment.

(D)Proportion of CD24high cells over a 7-day time course of JQ1 treatment (three-way ANOVA p < 0.01).

(E) Proportion of CD24high cells after BRD4 CRISPRi (Welch’s t test p < 0.01).

(F) Representative plots of annexin V and PI staining in K562 cells pretreated with either DMSO or JQ1 (250 nM) and subsequently treated for 48 h with either DMSO or imatinib (1 μM).

(G) Quantification of (F) (two-way ANOVA p < 0.01).

See also Figures S5 and S6. Bars represent means; error bars denote standard deviations. Experiments were performed in triplicate. DMSO, dimethyl sulfoxide; SSC, side scatter; CRISPRi, CRISPR interference; NT, non-targeting; gRNA, guide RNA; IMA, imatinib; PI, propidium iodide.